Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Europa
Biomarin Pharmaceutical Inc.
Nieuws
Biomarin Pharmaceutical Inc.
BM8
XET
: BM8
| ISIN: US09061G1013
24/11/2023
81,02 EUR
(-0,12%)
(-0,12%)
24/11/2023
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
4 september 2024 ·
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
· Persbericht
4 september 2024 ·
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
· Persbericht
29 augustus 2024 ·
BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
· Persbericht
21 augustus 2024 ·
BioMarin Announces New R&D and Business Development Leadership
· Persbericht
19 augustus 2024 ·
BioMarin to Host 2024 Investor Day on September 4th in New York
· Persbericht
5 augustus 2024 ·
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
· Persbericht
5 augustus 2024 ·
BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy
· Persbericht
24 juli 2024 ·
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
· Persbericht
23 juli 2024 ·
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET
· Persbericht
17 juni 2024 ·
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
· Persbericht
8 juni 2024 ·
KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
· Persbericht
7 juni 2024 ·
BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress
· Persbericht
8 mei 2024 ·
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
· Persbericht
4 mei 2024 ·
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
· Persbericht
24 april 2024 ·
BioMarin Reports Record Financial Results for the First Quarter 2024
· Persbericht
10 april 2024 ·
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
· Persbericht
12 maart 2024 ·
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
· Persbericht
7 maart 2024 ·
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
· Persbericht
1 maart 2024 ·
BioMarin Scheduled to Participate in March Investor Conferences
· Persbericht
22 februari 2024 ·
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe